noom glp 1 microdose reviews Launches GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program Noom to Sell Microdoses of

GLP-1 Drugs Linked to Reduced Risk of Depression and Bipolar Disorder According to a new study published in Translational Psychiatry , lifelong genetic activation of the glucagon-like peptide-1 receptor (GLP-1R) was linked with better mental well-being and significantly lower odds of major depressive disorder and bipolar disorder

Semaglutide is a human GLP-1 receptor agonist that mimics how exendin-4 signals the pancreas to release insulin when blood sugar rises

An initial decline in eGFR is common after treatment initiation but typically stabilizes over time, contributing to long-term preservation of kidney function [108]

Tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, generated $36.5 billion in combined sales in 2025 making it the single best-selling drug in the world, ahead of Mercks Keytruda at $31.7 billion (BioPharma Dive, 2026)